RxDoctor Payments Data

William Walker, MD

Pulmonary Disease · Anderson, SCNPI 1700889904

Payments from drug & device makers

$3,287in general payments, 2019–2025

Across 202 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$520
  • Boehringer Ingelheim$419
  • AstraZeneca$391
  • Electromed, Inc.$250
  • Insmed, Inc.$202
  • Merck$169
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,23798%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,287 in reported general payments places this provider in the 50th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$70,363
Medicare patients
228
Services billed
776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr16$242,719
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$134,660
Breztri AerosphereBudesonide/Glycopyr/Formoterol67$52,905
Breo ElliptaFluticasone/Vilanterol47$29,916
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$26,652
Combivent RespimatIpratropium/Albuterol Sulfate21$15,608
SymbicortBudesonide/Formoterol Fumarate47$15,089
EliquisApixaban20$12,581
DuleraMometasone/Formoterol18$6,361
Albuterol Sulfate HfaAlbuterol Sulfate149$5,146
Wixela InhubFluticasone Propion/Salmeterol15$968
Ventolin HfaAlbuterol Sulfate16$883
Azelastine Hcl12$838
Azithromycin56$680
Rifampin12$646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$202$242,71916 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$520$191,228268 claims
AstraZenecaBreztri Aerosphere, Symbicort$391$67,994114 claims
Boehringer IngelheimCombivent Respimat$419$15,60821 claims
PfizerEliquis$42$12,58120 claims
MerckDulera$169$6,36118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →